alexa Implementation of a Robust Pharmacovigilance Method for Filgrastim Non-Innovator Products in Cancer Patients in Routine Clinical Practice Complying With Mexican Regulations for Biocomparables
ISSN: 2329-6887

Journal of Pharmacovigilance
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Implementation of a Robust Pharmacovigilance Method for Filgrastim Non-Innovator Products in Cancer Patients in Routine Clinical Practice Complying With Mexican Regulations for Biocomparables

Huerta-Sanchez Olivid Marisol1, Aguilar-Ponce José Luis2, Meneses-García Abelardo2, Herrera-Gómez Ángel2, Herrera-Hernández Ricardo2, Monroy-Cruz María Teresa2, Burgeño-Ferreira Juan Andrés3, Castañeda-Hernández Gilberto1 and López-Gamboa Mireya1,2,4*
1Departamento de Farmacología, Cinvestav, IPN, Mexico City, Mexico
2Instituto Nacional de Cancerología, Mexico City, Mexico
3Biometriccs and Statistics Unit Centro Internacional de Mejoramiento del Maíz y Trigo INT, México
4Pro Pharma Research Organization S.A. de C.V., Mexico City, Mexico
Corresponding Author : Mireya López-Gamboa
Prol. Emperadores #298, Col. Emperadores
Del. Benito Juárez
México City, Mexico, CP 03320
Tel: 52 55 63 07 97
E-mail: [email protected] propharmaresearch.com
Received: July 31, 2015 Accepted: August 07, 2015 Published: August 10, 2015
Citation: Marisol HSO, Luis APJ, Abelardo MG, Ángel HG, Ricardo HH, et al. (2015) Implementation of a Robust Pharmacovigilance Method for Filgrastim Non-Innovator Products in Cancer Patients in Routine Clinical Practice Complying With Mexican Regulations for Biocomparables. J Pharmacovigilance 3:174. doi:10.4172/2329-6887.1000174
Copyright: © 2015 Marisol HSO, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed, Scholar Google

Abstract

Background and aim: Mexico, as other countries, has recently changed regulatory requirements for noninnovator biopharmaceuticals (biocomparables); a suitable pharmacovigilance program being now mandatory. Hence, our aim was to implement a robust pharmacovigilance method for filgrastim products of different brands used in routine clinical practice in Mexico.

Method: Prospective, phase IV, non-interventional study performed at the Instituto Nacional de Cancerología (National Institute of Cancerology) of Mexico. All pharmacy dispensations of filgrastim products were reviewed and recorded during four months. Patients received a diary for voluntary notation of adverse drug reactions (ADR) every time they were dispensed filgrastim. Additionally, medical records were consulted and contrasted with patientgenerated information. ADR analysis was performed according to the Mexican official norm on pharmacovigilance NOM-220-SSA1-2012.

Results: The procedure allowed to trace which filgrastim brand was administered to every patient. 373 patients received diaries. 214 patients returned diaries with information suitable for further analysis. Very common ADRs were musculoskeletal pain and headache. Common ADR were pain in extremities, asthenia, general body pain, nausea, pain in site of injection, vomit, paresthesia, abdominal discomfort, decreased appetite and diarrhoea. All ADRs were probably or possibly related to filgrastim and corresponded to previously reported ADRs. No new ADRs were detected.

Conclusion: The used methodology was robust enough to identify and characterize ADRs for each filgrastim brand product directly from patient information. It thus allows performing pharmacovigilance studies for biopharmaceuticals, both innovator and non-innovator, guaranteeing traceability and complying with current Mexican regulations for biocomparables.

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version